A Phase I Study of CI-8993 Immunotherapy in People with Mesothelioma

Share
Print

Full Title

Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumor Malignancies

Purpose

The purpose of this study is to find the highest dose of the investigational immunotherapy drug CI-8993 that can be given safely in people with metastatic mesothelioma that has come back or continued to grow after prior treatment. CI-8993 is designed to target a protein called VISTA, which prevents the immune system from attacking cancer cells. By blocking VISTA, CI-8993 may help the immune system to better attack cancer cells. CI-8993 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Participants must have metastatic mesothelioma that has come back or continued to grow after prior treatment.
  • They should recover from the serious side effects of prior therapies before receiving CI-8993.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, they must be well enough that they would be able to carry out office work or light housework.
  • This study is for people age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Marjorie Zauderer at 646-608-3790.

Protocol

21-302

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

Diseases